Alimera Sciences
Alimera Sciences Inc. is ready to launch in the US its recently approved intravitreal implant, Iluvien, for treating diabetic macular edema. President and CEO Dan Myers reported the company has a direct sales force of 32 reps ready for the product’s commercial debut in Q1 2015. Iluvien delivers a corticosteroid, providing sustained therapeutic effect for up to three years with one injection/implantation.
Presenter:
Dan Myers
Dan Myers is the Co-Founder, President, and CEO of Alimera Sciences, Inc. Under Dan’s leadership Alimera has commercially launched ILUVIEN®, Alimera’s lead product, in the US, UK, Germany and Portugal with Marketing Authorizations in an additional 14 countries throughout the EU.